|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure. |
| 公司地址
| 2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5 |
| 電話號碼
| +1 289 910-0850 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cardiolrx.com |
| 員工數量
| 23 |
| Mr. Christopher J. Waddick, C.A.,C.P.A.,M.B.A. |
Director, Chief Financial Officer and Corporate Secretary |
美元 220.00K |
31/03/2026 |
| Mr. David G. Elsley, M.B.A. |
Director, President and Chief Executive Officer |
美元 525.00K |
31/03/2026 |
| Dr. Andrew Hamer, M.D. |
Chief Medical Officer and Head, Research and Development |
美元 576.62K |
31/03/2026 |
| Mr. Bernard Lim |
Chief Operating Officer |
美元 385.00K |
31/03/2026 |
|
|
| Mr. Christopher J. Waddick, C.A.,C.P.A.,M.B.A. |
Director, Chief Financial Officer and Corporate Secretary |
31/03/2026 |
| Mr. David G. Elsley, M.B.A. |
Director, President and Chief Executive Officer |
31/03/2026 |
| Ms. Jennifer Chao |
Independent Director |
31/03/2026 |
| Mr. Peter Pekos, B.Sc. ,M.Sc. |
Independent Director |
31/03/2026 |
| Dr. Guillermo Torre-Amione, M.D.,PhD |
Chairman of the Board |
31/03/2026 |
| Mr. Colin G. Stott |
Independent Director |
31/03/2026 |
| Ms. Teri Loxam, M.B.A. |
Independent Director |
31/03/2026 |
| Dr. Timothy John Garnett, M.B.B.S. |
Independent Director |
31/03/2026 |
|
|
|
|